Intellia Therapeutics (NASDAQ:NTLA) Raised to Hold at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a sell rating to a hold rating in a research note published on Thursday, BidAskClub reports.

A number of other equities analysts have also issued reports on NTLA. Robert W. Baird assumed coverage on Intellia Therapeutics in a research note on Monday, July 8th. They set an outperform rating and a $23.00 price target for the company. ValuEngine lowered Intellia Therapeutics from a buy rating to a hold rating in a research note on Monday, August 26th. Chardan Capital reaffirmed a buy rating and set a $57.50 price target on shares of Intellia Therapeutics in a research note on Tuesday, May 28th. Roth Capital initiated coverage on Intellia Therapeutics in a research note on Monday, June 10th. They set a neutral rating and a $16.00 price objective for the company. Finally, Zacks Investment Research lowered Intellia Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 8th. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $25.56.

Shares of Intellia Therapeutics stock traded down $0.50 on Thursday, reaching $14.25. 17,014 shares of the company were exchanged, compared to its average volume of 458,291. The company has a quick ratio of 7.99, a current ratio of 7.99 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average is $16.18 and its two-hundred day moving average is $16.04. Intellia Therapeutics has a 1-year low of $11.03 and a 1-year high of $32.95.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.05. The firm had revenue of $11.10 million for the quarter, compared to analysts’ expectations of $7.15 million. Intellia Therapeutics had a negative return on equity of 33.03% and a negative net margin of 242.65%. The firm’s revenue was up 44.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.52) EPS. Equities research analysts forecast that Intellia Therapeutics will post -2.29 earnings per share for the current year.

Several institutional investors have recently modified their holdings of NTLA. BNP Paribas Arbitrage SA boosted its position in shares of Intellia Therapeutics by 942.0% in the first quarter. BNP Paribas Arbitrage SA now owns 7,648 shares of the company’s stock worth $131,000 after buying an additional 6,914 shares during the period. Janney Montgomery Scott LLC boosted its position in shares of Intellia Therapeutics by 6.7% in the first quarter. Janney Montgomery Scott LLC now owns 30,983 shares of the company’s stock worth $529,000 after buying an additional 1,936 shares during the period. Rhumbline Advisers boosted its position in shares of Intellia Therapeutics by 11.9% in the first quarter. Rhumbline Advisers now owns 53,847 shares of the company’s stock worth $920,000 after buying an additional 5,716 shares during the period. State Treasurer State of Michigan acquired a new stake in shares of Intellia Therapeutics in the first quarter worth $209,000. Finally, Moors & Cabot Inc. acquired a new stake in shares of Intellia Therapeutics in the first quarter worth $184,000. 79.39% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Featured Article: Preferred Stock

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Short Interest in Beyondspring Inc  Rises By 9.4%
Short Interest in Beyondspring Inc Rises By 9.4%
Acropolis Investment Management LLC Increases Stock Holdings in Vanguard Mortgage-Backed Securities ETF
Acropolis Investment Management LLC Increases Stock Holdings in Vanguard Mortgage-Backed Securities ETF
Vanguard Mid-Cap ETF  Shares Purchased by Acropolis Investment Management LLC
Vanguard Mid-Cap ETF Shares Purchased by Acropolis Investment Management LLC
CSI Compressco LP  Sees Significant Increase in Short Interest
CSI Compressco LP Sees Significant Increase in Short Interest
Alphabet Inc  Position Increased by Beacon Financial Group
Alphabet Inc Position Increased by Beacon Financial Group
Beacon Financial Group Sells 295 Shares of Anheuser Busch Inbev NV
Beacon Financial Group Sells 295 Shares of Anheuser Busch Inbev NV


© 2006-2019 Ticker Report